PSU Profiles
Keywords
Last Name
Institution

Eric Harvill

TitleProfessor of Microbiology and Infectious Disease
InstitutionCollege of Agricultural Sciences
DepartmentVeterinary and Biomedical Sciences
AddressW213 Millennium Science Cmplx
University Park, PA 16802
Phone8148638522
Other Positions
InstitutionHuck Institutes of the Life Sciences


 Overview 
 overview
PREFERRED TITLE/ROLE:

Professor of Microbiology and Infectious Disease

GRADUATE PROGRAM AFFILIATIONS:

Bioinformatics and Genomics, Cell and Developmental Biology, Genetics, Immunology and Infectious Diseases, Molecular Medicine

EDUCATION:

B.S. with Honors in Molecular and Cell Biology, University Scholars Program, The Pennsylvania State University
Ph.D., Microbiology and Molecular Genetics, University of California, Los Angeles
Postdoctoral Training, Department of Microbiology and Immunology, University of California, Los Angeles

NARRATIVE:

Dr. Harvill's research focuses on interactions between bacterial pathogens (primarily Bordetella spp.) and the host immune system, including virulence factors, host immune functions and genomics.


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Bolotin S, Harvill ET, Crowcroft NS. What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine. Pathog Dis. 2015 Nov; 73(8).
    View in: PubMed
  2. Hester SE, Goodfield LL, Park J, Feaga HA, Ivanov YV, Bendor L, Taylor DL, Harvill ET. Host Specificity of Ovine Bordetella parapertussis and the Role of Complement. PLoS One. 2015; 10(7):e0130964.
    View in: PubMed
  3. Register KB, Ivanov YV, Jacobs N, Meyer JA, Goodfield LL, Muse SJ, Smallridge WE, Brinkac L, Kim M, Sanka R, Harvill ET, Losada L. Draft Genome Sequences of 53 Genetically Distinct Isolates of Bordetella bronchiseptica Representing 11 Terrestrial and Aquatic Hosts. Genome Announc. 2015; 3(2).
    View in: PubMed
  4. Register KB, Ivanov YV, Harvill ET, Brinkac L, Kim M, Losada L. Draft Genome Sequences of Six Bordetella hinzii Isolates Acquired from Avian and Mammalian Hosts. Genome Announc. 2015; 3(2).
    View in: PubMed
  5. Shabbir MZ, Malys T, Ivanov YV, Park J, Shabbir MA, Rabbani M, Yaqub T, Harvill ET. Microbial communities present in the lower respiratory tract of clinically healthy birds in Pakistan. Poult Sci. 2015 Apr; 94(4):612-20.
    View in: PubMed
  6. Register KB, Ivanov YV, Harvill ET, Davison N, Foster G. Novel, host-restricted genotypes of Bordetella bronchiseptica associated with phocine respiratory tract isolates. Microbiology. 2015 Mar; 161(Pt 3):580-92.
    View in: PubMed
  7. Gorgojo J, Harvill ET, Rodríguez ME. Bordetella parapertussis Survives inside Human Macrophages in Lipid Raft-Enriched Phagosomes. Infect Immun. 2014 Dec; 82(12):5175-84.
    View in: PubMed
  8. Place DE, Muse SJ, Kirimanjeswara GS, Harvill ET. Caspase-1-independent interleukin-1ß is required for clearance of Bordetella pertussis infections and whole-cell vaccine-mediated immunity. PLoS One. 2014; 9(9):e107188.
    View in: PubMed
  9. Harvill ET, Goodfield LL, Ivanov Y, Smallridge WE, Meyer JA, Cassiday PK, Tondella ML, Brinkac L, Sanka R, Kim M, Losada L. Genome Sequences of Nine Bordetella holmesii Strains Isolated in the United States. Genome Announc. 2014; 2(3).
    View in: PubMed
  10. Bart MJ, Harris SR, Advani A, Arakawa Y, Bottero D, Bouchez V, Cassiday PK, Chiang CS, Dalby T, Fry NK, Gaillard ME, van Gent M, Guiso N, Hallander HO, Harvill ET, He Q, van der Heide HG, Heuvelman K, Hozbor DF, Kamachi K, Karataev GI, Lan R, Lutylska A, Maharjan RP, Mertsola J, Miyamura T, Octavia S, Preston A, Quail MA, Sintchenko V, Stefanelli P, Tondella ML, Tsang RS, Xu Y, Yao SM, Zhang S, Parkhill J, Mooi FR. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio. 2014; 5(2):e01074.
    View in: PubMed
  11. Hewlett EL, Burns DL, Cotter PA, Harvill ET, Merkel TJ, Quinn CP, Stibitz ES. Pertussis pathogenesis--what we know and what we don't know. J Infect Dis. 2014 Apr 1; 209(7):982-5.
    View in: PubMed
  12. Rolin O, Smallridge W, Henry M, Goodfield L, Place D, Harvill ET. Toll-like receptor 4 limits transmission of Bordetella bronchiseptica. PLoS One. 2014; 9(1):e85229.
    View in: PubMed
  13. Smallridge WE, Rolin OY, Jacobs NT, Harvill ET. Different effects of whole-cell and acellular vaccines on Bordetella transmission. J Infect Dis. 2014 Jun 15; 209(12):1981-8.
    View in: PubMed
  14. Harvill ET, Goodfield LL, Ivanov Y, Meyer JA, Newth C, Cassiday P, Tondella ML, Liao P, Zimmerman J, Meert K, Wessel D, Berger J, Dean JM, Holubkov R, Burr J, Liu T, Brinkac L, Kim M, Losada L. Genome Sequences of 28 Bordetella pertussis U.S. Outbreak Strains Dating from 2010 to 2012. Genome Announc. 2013; 1(6).
    View in: PubMed
  15. Weyrich LS, Feaga HA, Park J, Muse SJ, Safi CY, Rolin OY, Young SE, Harvill ET. Resident microbiota affect Bordetella pertussis infectious dose and host specificity. J Infect Dis. 2014 Mar; 209(6):913-21.
    View in: PubMed
  16. Rolin O, Muse SJ, Safi C, Elahi S, Gerdts V, Hittle LE, Ernst RK, Harvill ET, Preston A. Enzymatic modification of lipid A by ArnT protects Bordetella bronchiseptica against cationic peptides and is required for transmission. Infect Immun. 2014 Feb; 82(2):491-9.
    View in: PubMed
  17. Hester SE, Park J, Goodfield LL, Feaga HA, Preston A, Harvill ET. Horizontally acquired divergent O-antigen contributes to escape from cross-immunity in the classical bordetellae. BMC Evol Biol. 2013; 13:209.
    View in: PubMed
  18. Berger JT, Carcillo JA, Shanley TP, Wessel DL, Clark A, Holubkov R, Meert KL, Newth CJ, Berg RA, Heidemann S, Harrison R, Pollack M, Dalton H, Harvill E, Karanikas A, Liu T, Burr JS, Doctor A, Dean JM, Jenkins TL, Nicholson CE. Critical pertussis illness in children: a multicenter prospective cohort study. Pediatr Crit Care Med. 2013 May; 14(4):356-65.
    View in: PubMed
  19. Harvill ET. Cultivating our "frienemies": viewing immunity as microbiome management. MBio. 2013; 4(2).
    View in: PubMed
  20. Weyrich LS, Harvill ET. Teaching ethical aptitude to graduate student researchers. Account Res. 2013; 20(1):5-12.
    View in: PubMed
  21. Lass S, Hudson PJ, Thakar J, Saric J, Harvill E, Albert R, Perkins SE. Generating super-shedders: co-infection increases bacterial load and egg production of a gastrointestinal helminth. J R Soc Interface. 2013 Mar 6; 10(80):20120588.
    View in: PubMed
  22. Zhang X, Weyrich LS, Lavine JS, Karanikas AT, Harvill ET. Lack of cross-protection against Bordetella holmesii after pertussis vaccination. Emerg Infect Dis. 2012 Nov; 18(11):1771-9.
    View in: PubMed
  23. Hester SE, Lui M, Nicholson T, Nowacki D, Harvill ET. Identification of a CO2 responsive regulon in Bordetella. PLoS One. 2012; 7(10):e47635.
    View in: PubMed
  24. Weyrich LS, Rolin OY, Muse SJ, Park J, Spidale N, Kennett MJ, Hester SE, Chen C, Dudley EG, Harvill ET. A Type VI secretion system encoding locus is required for Bordetella bronchiseptica immunomodulation and persistence in vivo. PLoS One. 2012; 7(10):e45892.
    View in: PubMed
  25. Park J, Zhang Y, Buboltz AM, Zhang X, Schuster SC, Ahuja U, Liu M, Miller JF, Sebaihia M, Bentley SD, Parkhill J, Harvill ET. Comparative genomics of the classical Bordetella subspecies: the evolution and exchange of virulence-associated diversity amongst closely related pathogens. BMC Genomics. 2012; 13:545.
    View in: PubMed
  26. Gorgojo J, Lamberti Y, Valdez H, Harvill ET, Rodríguez ME. Bordetella parapertussis survives the innate interaction with human neutrophils by impairing bactericidal trafficking inside the cell through a lipid raft-dependent mechanism mediated by the lipopolysaccharide O antigen. Infect Immun. 2012 Dec; 80(12):4309-16.
    View in: PubMed
  27. Barchinger SE, Zhang X, Hester SE, Rodriguez ME, Harvill ET, Ades SE. sigE facilitates the adaptation of Bordetella bronchiseptica to stress conditions and lethal infection in immunocompromised mice. BMC Microbiol. 2012; 12:179.
    View in: PubMed
  28. Ahuja U, Liu M, Tomida S, Park J, Souda P, Whitelegge J, Li H, Harvill ET, Parkhill J, Miller JF. Phenotypic and genomic analysis of hypervirulent human-associated Bordetella bronchiseptica. BMC Microbiol. 2012; 12:167.
    View in: PubMed
  29. Burr JS, Jenkins TL, Harrison R, Meert K, Anand KJ, Berger JT, Zimmerman J, Carcillo J, Dean JM, Newth CJ, Willson DF, Sanders RC, Pollack MM, Harvill E, Nicholson CE. The Collaborative Pediatric Critical Care Research Network Critical Pertussis Study: collaborative research in pediatric critical care medicine. Pediatr Crit Care Med. 2011 Jul; 12(4):387-92.
    View in: PubMed
  30. Zhang X, Goel T, Goodfield LL, Muse SJ, Harvill ET. Decreased leukocyte accumulation and delayed Bordetella pertussis clearance in IL-6-/- mice. J Immunol. 2011 Apr 15; 186(8):4895-904.
    View in: PubMed
  31. Long GH, Sinha D, Read AF, Pritt S, Kline B, Harvill ET, Hudson PJ, Bjørnstad ON. Identifying the age cohort responsible for transmission in a natural outbreak of Bordetella bronchiseptica. PLoS Pathog. 2010; 6(12):e1001224.
    View in: PubMed
  32. Lavine J, Broutin H, Harvill ET, Bjørnstad ON. Imperfect vaccine-induced immunity and whooping cough transmission to infants. Vaccine. 2010 Dec 10; 29(1):11-6.
    View in: PubMed
  33. Zhang X, Hester SE, Kennett MJ, Karanikas AT, Bendor L, Place DE, Harvill ET. Interleukin-1 receptor signaling is required to overcome the effects of pertussis toxin and for efficient infection- or vaccination-induced immunity against Bordetella pertussis. Infect Immun. 2011 Jan; 79(1):527-41.
    View in: PubMed
  34. Pathak AK, Boag B, Poss M, Harvill ET, Cattadori IM. Seasonal breeding drives the incidence of a chronic bacterial infection in a free-living herbivore population. Epidemiol Infect. 2011 Aug; 139(8):1210-9.
    View in: PubMed
  35. Vinogradov E, King JD, Pathak AK, Harvill ET, Preston A. Antigenic Variation among Bordetella: Bordetella bronchiseptica strain MO149 expresses a novel o chain that is poorly immunogenic. J Biol Chem. 2010 Aug 27; 285(35):26869-77.
    View in: PubMed
  36. Long GH, Karanikas AT, Harvill ET, Read AF, Hudson PJ. Acellular pertussis vaccination facilitates Bordetella parapertussis infection in a rodent model of bordetellosis. Proc Biol Sci. 2010 Jul 7; 277(1690):2017-25.
    View in: PubMed
  37. Lamberti YA, Hayes JA, Perez Vidakovics ML, Harvill ET, Rodriguez ME. Intracellular trafficking of Bordetella pertussis in human macrophages. Infect Immun. 2010 Mar; 78(3):907-13.
    View in: PubMed
  38. Wolfe DN, Karanikas AT, Hester SE, Kennett MJ, Harvill ET. IL-10 induction by Bordetella parapertussis limits a protective IFN-gamma response. J Immunol. 2010 Feb 1; 184(3):1392-400.
    View in: PubMed
  39. Zhang X, Rodríguez ME, Harvill ET. O antigen allows B. parapertussis to evade B. pertussis vaccine-induced immunity by blocking binding and functions of cross-reactive antibodies. PLoS One. 2009; 4(9):e6989.
    View in: PubMed
  40. Zhang X, Goebel EM, Rodríguez ME, Preston A, Harvill ET. The O antigen is a critical antigen for the development of a protective immune response to Bordetella parapertussis. Infect Immun. 2009 Nov; 77(11):5050-8.
    View in: PubMed
  41. Goebel EM, Zhang X, Harvill ET. Bordetella pertussis infection or vaccination substantially protects mice against B. bronchiseptica infection. PLoS One. 2009; 4(8):e6778.
    View in: PubMed
  42. Nicholson TL, Buboltz AM, Harvill ET, Brockmeier SL. Microarray and functional analysis of growth phase-dependent gene regulation in Bordetella bronchiseptica. Infect Immun. 2009 Oct; 77(10):4221-31.
    View in: PubMed
  43. Buboltz AM, Nicholson TL, Weyrich LS, Harvill ET. Role of the type III secretion system in a hypervirulent lineage of Bordetella bronchiseptica. Infect Immun. 2009 Sep; 77(9):3969-77.
    View in: PubMed
  44. Buboltz AM, Nicholson TL, Karanikas AT, Preston A, Harvill ET. Evidence for horizontal gene transfer of two antigenically distinct O antigens in Bordetella bronchiseptica. Infect Immun. 2009 Aug; 77(8):3249-57.
    View in: PubMed
  45. King AA, Shrestha S, Harvill ET, Bjørnstad ON. Evolution of acute infections and the invasion-persistence trade-off. Am Nat. 2009 Apr; 173(4):446-55.
    View in: PubMed
  46. Wolfe DN, Buboltz AM, Harvill ET. Inefficient Toll-like receptor-4 stimulation enables Bordetella parapertussis to avoid host immunity. PLoS One. 2009; 4(1):e4280.
    View in: PubMed
  47. Thakar J, Saadatpour-Moghaddam A, Harvill ET, Albert R. Constraint-based network model of pathogen-immune system interactions. J R Soc Interface. 2009 Jul 6; 6(36):599-612.
    View in: PubMed
  48. Buboltz AM, Nicholson TL, Parette MR, Hester SE, Parkhill J, Harvill ET. Replacement of adenylate cyclase toxin in a lineage of Bordetella bronchiseptica. J Bacteriol. 2008 Aug; 190(15):5502-11.
    View in: PubMed
  49. Paul S, Bag SK, Das S, Harvill ET, Dutta C. Molecular signature of hypersaline adaptation: insights from genome and proteome composition of halophilic prokaryotes. Genome Biol. 2008; 9(4):R70.
    View in: PubMed
  50. Harvill ET, Osorio M, Loving CL, Lee GM, Kelly VK, Merkel TJ. Anamnestic protective immunity to Bacillus anthracis is antibody mediated but independent of complement and Fc receptors. Infect Immun. 2008 May; 76(5):2177-82.
    View in: PubMed
  51. Goebel EM, Wolfe DN, Elder K, Stibitz S, Harvill ET. O antigen protects Bordetella parapertussis from complement. Infect Immun. 2008 Apr; 76(4):1774-80.
    View in: PubMed
  52. Restif O, Wolfe DN, Goebel EM, Bjornstad ON, Harvill ET. Of mice and men: asymmetric interactions between Bordetella pathogen species. Parasitology. 2008 Nov; 135(13):1517-29.
    View in: PubMed
  53. Wolfe DN, Mann PB, Buboltz AM, Harvill ET. Delayed role of tumor necrosis factor- alpha in overcoming the effects of pertussis toxin. J Infect Dis. 2007 Oct 15; 196(8):1228-36.
    View in: PubMed
  54. Wolfe DN, Goebel EM, Bjornstad ON, Restif O, Harvill ET. The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity. Infect Immun. 2007 Oct; 75(10):4972-9.
    View in: PubMed
  55. Wolfe DN, Kirimanjeswara GS, Goebel EM, Harvill ET. Comparative role of immunoglobulin A in protective immunity against the Bordetellae. Infect Immun. 2007 Sep; 75(9):4416-22.
    View in: PubMed
  56. Thakar J, Pilione M, Kirimanjeswara G, Harvill ET, Albert R. Modeling systems-level regulation of host immune responses. PLoS Comput Biol. 2007 Jun; 3(6):e109.
    View in: PubMed
  57. Mann P, Goebel E, Barbarich J, Pilione M, Kennett M, Harvill E. Use of a genetically defined double mutant strain of Bordetella bronchiseptica lacking adenylate cyclase and type III secretion as a live vaccine. Infect Immun. 2007 Jul; 75(7):3665-72.
    View in: PubMed
  58. Gopinathan L, Kirimanjeswara GS, Wolfe DN, Kelley ML, Harvill ET. Different mechanisms of vaccine-induced and infection-induced immunity to Bordetella bronchiseptica. Microbes Infect. 2007 Apr; 9(4):442-8.
    View in: PubMed
  59. MacArthur I, Mann PB, Harvill ET, Preston A. IEIIS Meeting minireview: Bordetella evolution: lipid A and Toll-like receptor 4. J Endotoxin Res. 2007; 13(4):243-7.
    View in: PubMed
  60. Joo J, Gunny M, Cases M, Hudson P, Albert R, Harvill E. Bacteriophage-mediated competition in Bordetella bacteria. Proc Biol Sci. 2006 Jul 22; 273(1595):1843-8.
    View in: PubMed
  61. Pilione MR, Agosto LM, Kennett MJ, Harvill ET. CD11b is required for the resolution of inflammation induced by Bordetella bronchiseptica respiratory infection. Cell Microbiol. 2006 May; 8(5):758-68.
    View in: PubMed
  62. Pilione MR, Harvill ET. The Bordetella bronchiseptica type III secretion system inhibits gamma interferon production that is required for efficient antibody-mediated bacterial clearance. Infect Immun. 2006 Feb; 74(2):1043-9.
    View in: PubMed
  63. Mann PB, Wolfe D, Latz E, Golenbock D, Preston A, Harvill ET. Comparative toll-like receptor 4-mediated innate host defense to Bordetella infection. Infect Immun. 2005 Dec; 73(12):8144-52.
    View in: PubMed
  64. Kirimanjeswara GS, Mann PB, Pilione M, Kennett MJ, Harvill ET. The complex mechanism of antibody-mediated clearance of Bordetella from the lungs requires TLR4. J Immunol. 2005 Dec 1; 175(11):7504-11.
    View in: PubMed
  65. Kirimanjeswara GS, Agosto LM, Kennett MJ, Bjornstad ON, Harvill ET. Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J Clin Invest. 2005 Dec; 115(12):3594-601.
    View in: PubMed
  66. Hughes MA, Green CS, Lowchyj L, Lee GM, Grippe VK, Smith MF, Huang LY, Harvill ET, Merkel TJ. MyD88-dependent signaling contributes to protection following Bacillus anthracis spore challenge of mice: implications for Toll-like receptor signaling. Infect Immun. 2005 Nov; 73(11):7535-40.
    View in: PubMed
  67. Wolfe DN, Kirimanjeswara GS, Harvill ET. Clearance of Bordetella parapertussis from the lower respiratory tract requires humoral and cellular immunity. Infect Immun. 2005 Oct; 73(10):6508-13.
    View in: PubMed
  68. Skinner JA, Pilione MR, Shen H, Harvill ET, Yuk MH. Bordetella type III secretion modulates dendritic cell migration resulting in immunosuppression and bacterial persistence. J Immunol. 2005 Oct 1; 175(7):4647-52.
    View in: PubMed
  69. Bjørnstad ON, Harvill ET. Evolution and emergence of Bordetella in humans. Trends Microbiol. 2005 Aug; 13(8):355-9.
    View in: PubMed
  70. Harvill ET, Lee G, Grippe VK, Merkel TJ. Complement depletion renders C57BL/6 mice sensitive to the Bacillus anthracis Sterne strain. Infect Immun. 2005 Jul; 73(7):4420-2.
    View in: PubMed
  71. Mann PB, Elder KD, Kennett MJ, Harvill ET. Toll-like receptor 4-dependent early elicited tumor necrosis factor alpha expression is critical for innate host defense against Bordetella bronchiseptica. Infect Immun. 2004 Nov; 72(11):6650-8.
    View in: PubMed
  72. Elder KD, Harvill ET. Strain-dependent role of BrkA during Bordetella pertussis infection of the murine respiratory tract. Infect Immun. 2004 Oct; 72(10):5919-24.
    View in: PubMed
  73. Pilione MR, Pishko EJ, Preston A, Maskell DJ, Harvill ET. pagP is required for resistance to antibody-mediated complement lysis during Bordetella bronchiseptica respiratory infection. Infect Immun. 2004 May; 72(5):2837-42.
    View in: PubMed
  74. Liu M, Gingery M, Doulatov SR, Liu Y, Hodes A, Baker S, Davis P, Simmonds M, Churcher C, Mungall K, Quail MA, Preston A, Harvill ET, Maskell DJ, Eiserling FA, Parkhill J, Miller JF. Genomic and genetic analysis of Bordetella bacteriophages encoding reverse transcriptase-mediated tropism-switching cassettes. J Bacteriol. 2004 Mar; 186(5):1503-17.
    View in: PubMed
  75. Mann PB, Kennett MJ, Harvill ET. Toll-like receptor 4 is critical to innate host defense in a murine model of bordetellosis. J Infect Dis. 2004 Mar 1; 189(5):833-6.
    View in: PubMed
  76. Pishko EJ, Kirimanjeswara GS, Pilione MR, Gopinathan L, Kennett MJ, Harvill ET. Antibody-mediated bacterial clearance from the lower respiratory tract of mice requires complement component C3. Eur J Immunol. 2004 Jan; 34(1):184-93.
    View in: PubMed
  77. Pishko EJ, Betting DJ, Hutter CS, Harvill ET. Bordetella pertussis acquires resistance to complement-mediated killing in vivo. Infect Immun. 2003 Sep; 71(9):4936-42.
    View in: PubMed
  78. Preston A, Maxim E, Toland E, Pishko EJ, Harvill ET, Caroff M, Maskell DJ. Bordetella bronchiseptica PagP is a Bvg-regulated lipid A palmitoyl transferase that is required for persistent colonization of the mouse respiratory tract. Mol Microbiol. 2003 May; 48(3):725-36.
    View in: PubMed
  79. Kirimanjeswara GS, Mann PB, Harvill ET. Role of antibodies in immunity to Bordetella infections. Infect Immun. 2003 Apr; 71(4):1719-24.
    View in: PubMed
  80. Burns VC, Pishko EJ, Preston A, Maskell DJ, Harvill ET. Role of Bordetella O antigen in respiratory tract infection. Infect Immun. 2003 Jan; 71(1):86-94.
    View in: PubMed
  81. Heininger U, Cotter PA, Fescemyer HW, Martinez de Tejada G, Yuk MH, Miller JF, Harvill ET. Comparative phenotypic analysis of the Bordetella parapertussis isolate chosen for genomic sequencing. Infect Immun. 2002 Jul; 70(7):3777-84.
    View in: PubMed
  82. Le LQ, Kabarowski JH, Weng Z, Satterthwaite AB, Harvill ET, Jensen ER, Miller JF, Witte ON. Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity. 2001 May; 14(5):561-71.
    View in: PubMed
  83. Harvill ET, Preston A, Cotter PA, Allen AG, Maskell DJ, Miller JF. Multiple roles for Bordetella lipopolysaccharide molecules during respiratory tract infection. Infect Immun. 2000 Dec; 68(12):6720-8.
    View in: PubMed
  84. Yuk MH, Harvill ET, Cotter PA, Miller JF. Modulation of host immune responses, induction of apoptosis and inhibition of NF-kappaB activation by the Bordetella type III secretion system. Mol Microbiol. 2000 Mar; 35(5):991-1004.
    View in: PubMed
  85. Harvill ET, Miller JF. Manipulating the host to study bacterial virulence. Curr Opin Microbiol. 2000 Feb; 3(1):93-6.
    View in: PubMed
  86. Harvill ET, Cotter PA, Miller JF. Pregenomic comparative analysis between bordetella bronchiseptica RB50 and Bordetella pertussis tohama I in murine models of respiratory tract infection. Infect Immun. 1999 Nov; 67(11):6109-18.
    View in: PubMed
  87. Harvill ET, Cotter PA, Yuk MH, Miller JF. Probing the function of Bordetella bronchiseptica adenylate cyclase toxin by manipulating host immunity. Infect Immun. 1999 Mar; 67(3):1493-500.
    View in: PubMed
  88. Penichet ML, Harvill ET, Morrison SL. An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity. J Interferon Cytokine Res. 1998 Aug; 18(8):597-607.
    View in: PubMed
  89. Yuk MH, Harvill ET, Miller JF. The BvgAS virulence control system regulates type III secretion in Bordetella bronchiseptica. Mol Microbiol. 1998 Jun; 28(5):945-59.
    View in: PubMed
  90. Penichet ML, Harvill ET, Morrison SL. Antibody-IL-2 fusion proteins: a novel strategy for immune protection. Hum Antibodies. 1997; 8(3):106-18.
    View in: PubMed
  91. Sensel MG, Coloma MJ, Harvill ET, Shin SU, Smith RI, Morrison SL. Engineering novel antibody molecules. Chem Immunol. 1997; 65:129-58.
    View in: PubMed
  92. Harvill ET, Fleming JM, Morrison SL. In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. J Immunol. 1996 Oct 1; 157(7):3165-70.
    View in: PubMed
  93. Harvill ET, Morrison SL. An IgG3-IL-2 fusion protein has higher affinity than hrIL-2 for the IL-2R alpha subunit: real time measurement of ligand binding. Mol Immunol. 1996 Aug; 33(11-12):1007-14.
    View in: PubMed
  94. Harvill ET, Morrison SL. An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology. 1995 Aug; 1(2):95-105.
    View in: PubMed
Harvill's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_